TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Rhythm Biosciences Ltd. ( (AU:RHY) ) has provided an announcement.
Rhythm Biosciences Ltd announced the successful evaluation of its ColoSTAT® test, which demonstrates consistent performance in detecting colorectal cancer across various age groups and genders. The test shows promise for early onset cancer detection in patients under 50 years old, addressing a growing need in the healthcare industry. The company plans further studies to establish statistical significance and aims for commercial release following regulatory assessments.
More about Rhythm Biosciences Ltd.
Rhythm Biosciences Ltd (ASX: RHY) is an Australian medical diagnostics company focused on providing simple and affordable blood tests for early cancer detection. Founded in 2017 and headquartered in Melbourne, the company aims to improve patient outcomes and reduce the global cancer burden. Rhythm Biosciences collaborates with global partners to commercialize and distribute its diagnostic solutions.
Average Trading Volume: 816,738
Technical Sentiment Signal: Buy
Current Market Cap: A$31.63M
See more insights into RHY stock on TipRanks’ Stock Analysis page.